文章引用说明 更多>> (返回到该文章)

Kodahl, A.R., Lyng, M.B., Binder, H., Cold, S., Gravgaard, K., Knoop, A.S. and Ditzel, H.J. (2014) Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: A case control study. Molecular Oncology, 8, 874-883.
http://dx.doi.org/10.1016/j.molonc.2014.03.002

被以下文章引用:

  • 标题: 循环microRNAs在乳腺癌诊治中的应用The Diagnostic and Therapeutic Application of Circulating microRNAs in Breast Cancer

    作者: 薛丽, 白玉杰

    关键字: 微小核糖核酸, 乳腺癌, 生物标志, 诊断, 治疗microRNA, Breast Cancer, Biomarker, Diagnosis, Therapy

    期刊名称: 《Medical Diagnosis》, Vol.5 No.3, 2015-09-29

    摘要: 微小核糖核酸(microRNAs, miRNAs)是一类具有调控功能的小分子非编码核糖核酸,与肿瘤的发生有密切关系。大量研究也充分证实了miRNAs在乳腺癌中的作用。循环miRNAs (circulating miRNAs)指存在于血液或其他体液中的细胞外游离microRNAs,具有稳定性好、取材方便、创伤小,可反复取样检测等优点,且与肿瘤发生和发展相关,因此被认为是最具潜力的肿瘤标志之一。本综述主要总结循环miRNAs在乳腺癌早期诊断、预后预测及指导治疗等方面研究及其临床应用进展,并探讨循环miRNAs临床应用所面临的挑战和需解决的问题。 MicroRNAs (miRNAs) are a class of short non-coding regulatory RNAs with an etiological contribution to carcinogensis. The involvement of miRNAs in breast cancer has been reiterated and irrefutably proved by many studies. Circulating miRNAs refer to the cell free miRNAs in the blood or other body fluids, with characteristics such as remarkable stability, ease of access, minimal invasiveness, possibility of repeated sampling, and proven roles in cancer development and progression, so it has been regarded as one of the most potential biomarkers of tumor. This review focuses on recent-finding of circulating miRNAs as biomarkers in early diagnostic, prognostic indications and treatment selection, along with an appraisal of the translational implication of this field. We also addressed the future and the problems and challenges that need to be overcome to achieve clinical implementation of circulating miRNAs.

在线客服:
对外合作:
联系方式:400-6379-560
投诉建议:feedback@hanspub.org
客服号

人工客服,优惠资讯,稿件咨询
公众号

科技前沿与学术知识分享